细胞淋巴瘤-话题@MedSci

#细胞淋巴瘤#

385篇内容 | 5345人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1702565, encodeId=332f1e02565f8, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=MD安德森癌症中心开发的新药物，可有效克服套细胞淋巴瘤对依鲁替尼的耐药性, objectType=article, longId=165927, objectId=f92a16592e1c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f92a16592e1c, replyNumber=0, likeNumber=89, createdTime=2019-05-17, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f92a16592e1c, moduleTitle=MD安德森癌症中心开发的新药物，可有效克服套细胞淋巴瘤对依鲁替尼的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f92a16592e1c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702574, encodeId=c6ed1e025740e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=来那度胺在弥漫性大B细胞淋巴瘤中的应用继续闪耀, objectType=article, longId=168636, objectId=b21a168636d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b21a168636d1, replyNumber=0, likeNumber=68, createdTime=2019-09-07, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b21a168636d1, moduleTitle=来那度胺在弥漫性大B细胞淋巴瘤中的应用继续闪耀, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b21a168636d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702579, encodeId=56fb1e025797b, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：抗生素抑制皮肤T细胞淋巴瘤患者肿瘤和疾病活动, objectType=article, longId=176080, objectId=0dd41e60808f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0dd41e60808f, replyNumber=0, likeNumber=70, createdTime=2019-09-12, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0dd41e60808f, moduleTitle=Blood：抗生素抑制皮肤T细胞淋巴瘤患者肿瘤和疾病活动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0dd41e60808f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702550, encodeId=80871e025502a, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=膀胱弥漫大B细胞淋巴瘤侵及回肠1例, objectType=article, longId=158745, objectId=d7d4158e45d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7d4158e45d0, replyNumber=0, likeNumber=78, createdTime=2019-12-18, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7d4158e45d0, moduleTitle=膀胱弥漫大B细胞淋巴瘤侵及回肠1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7d4158e45d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702547, encodeId=deaf1e025470c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则, objectType=article, longId=157519, objectId=39d615e51935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39d615e51935, replyNumber=0, likeNumber=15, createdTime=2019-12-19, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39d615e51935, moduleTitle=专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39d615e51935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702558, encodeId=68bb1e02558e6, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：Venetoclax联合R-CHOP可安全有效治疗弥漫性大B细胞淋巴瘤, objectType=article, longId=162820, objectId=0e731628209a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e731628209a, replyNumber=0, likeNumber=69, createdTime=2019-05-10, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e731628209a, moduleTitle=Blood：Venetoclax联合R-CHOP可安全有效治疗弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e731628209a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702564, encodeId=03591e0256425, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Clin Cancer Res:弥漫性大B细胞淋巴瘤（DLBCL）治疗耐药新机制, objectType=article, longId=164689, objectId=774b16468924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=774b16468924, replyNumber=0, likeNumber=87, createdTime=2019-10-22, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=774b16468924, moduleTitle=Clin Cancer Res:弥漫性大B细胞淋巴瘤（DLBCL）治疗耐药新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=774b16468924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702525, encodeId=afd81e02525f6, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=【2018 CSH】吴德沛教授：CAR-T 中国应用与发展——在B细胞淋巴瘤治疗领域大放异彩, objectType=article, longId=152389, objectId=410f15238934, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=410f15238934, replyNumber=0, likeNumber=93, createdTime=2019-05-17, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=410f15238934, moduleTitle=【2018 CSH】吴德沛教授：CAR-T 中国应用与发展——在B细胞淋巴瘤治疗领域大放异彩, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=410f15238934)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702586, encodeId=08bf1e0258672, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：皮肤T细胞淋巴瘤：循环肿瘤细胞的皮肤定植, objectType=article, longId=179595, objectId=25831e9595b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25831e9595b7, replyNumber=0, likeNumber=75, createdTime=2019-09-26, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25831e9595b7, moduleTitle=Blood：皮肤T细胞淋巴瘤：循环肿瘤细胞的皮肤定植, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25831e9595b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702569, encodeId=90801e025694c, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NCCN临床实践指南：B细胞淋巴瘤（2019.V3）, objectType=article, longId=167558, objectId=09e316e558c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=09e316e558c2, replyNumber=0, likeNumber=25, createdTime=2020-04-27, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=09e316e558c2, moduleTitle=NCCN临床实践指南：B细胞淋巴瘤（2019.V3）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=09e316e558c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702573, encodeId=abfa1e0257379, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=B细胞淋巴瘤治疗：即使CAR-T疗法失败，还有双特异性抗体REGN1979, objectType=article, longId=168604, objectId=b8a016860474, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8a016860474, replyNumber=0, likeNumber=52, createdTime=2019-06-19, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8a016860474, moduleTitle=B细胞淋巴瘤治疗：即使CAR-T疗法失败，还有双特异性抗体REGN1979, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8a016860474)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702546, encodeId=e7261e0254674, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=NEJM：Tisagenlecleucel治疗复发或难治性弥漫性大B细胞淋巴瘤II期结果显著, objectType=article, longId=157227, objectId=faef15e22769, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faef15e22769, replyNumber=0, likeNumber=65, createdTime=2019-03-05, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faef15e22769, moduleTitle=NEJM：Tisagenlecleucel治疗复发或难治性弥漫性大B细胞淋巴瘤II期结果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faef15e22769)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702554, encodeId=63fd1e025544d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=加拿大批准Yescarta（Axicabtagene Ciloleucel）CAR T疗法治疗成人复发或难治性大B细胞淋巴瘤, objectType=article, longId=160891, objectId=16d216089137, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d216089137, replyNumber=0, likeNumber=64, createdTime=2019-03-09, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d216089137, moduleTitle=加拿大批准Yescarta（Axicabtagene Ciloleucel）CAR T疗法治疗成人复发或难治性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d216089137)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702523, encodeId=e50d1e0252367, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet oncol：VR-CAP疗法相比R-CHOP可显著延长套细胞淋巴瘤患者的总体存活期, objectType=article, longId=152211, objectId=8ea2152211a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ea2152211a2, replyNumber=0, likeNumber=67, createdTime=2019-04-27, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ea2152211a2, moduleTitle=Lancet oncol：VR-CAP疗法相比R-CHOP可显著延长套细胞淋巴瘤患者的总体存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ea2152211a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702567, encodeId=1b211e02567c7, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Lancet oncol：Polatuzumab vedotin联合免疫化疗用于弥漫性大B细胞淋巴瘤的安全性和疗效, objectType=article, longId=166508, objectId=9b0116650850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b0116650850, replyNumber=0, likeNumber=94, createdTime=2019-10-03, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b0116650850, moduleTitle=Lancet oncol：Polatuzumab vedotin联合免疫化疗用于弥漫性大B细胞淋巴瘤的安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b0116650850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702570, encodeId=42931e025702a, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：PD-L1在ALK+间变性大细胞淋巴瘤中表达上调的分子机制, objectType=article, longId=167595, objectId=5ad816e5956b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ad816e5956b, replyNumber=0, likeNumber=84, createdTime=2020-03-27, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ad816e5956b, moduleTitle=Blood：PD-L1在ALK+间变性大细胞淋巴瘤中表达上调的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ad816e5956b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702581, encodeId=b17b1e025812d, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：弥漫性大B细胞淋巴瘤CD37基因免疫优势位点的高发突变, objectType=article, longId=176755, objectId=ddc71e6755b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddc71e6755b1, replyNumber=0, likeNumber=73, createdTime=2020-05-04, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddc71e6755b1, moduleTitle=Blood：弥漫性大B细胞淋巴瘤CD37基因免疫优势位点的高发突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddc71e6755b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702553, encodeId=d0181e025531e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤, objectType=article, longId=159650, objectId=141815965033, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=141815965033, replyNumber=0, likeNumber=79, createdTime=2019-05-02, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=141815965033, moduleTitle=Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=141815965033)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702561, encodeId=19ec1e02561ec, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=原发性子宫及双侧附件弥漫性大B细胞淋巴瘤1例, objectType=article, longId=163896, objectId=6146163896f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6146163896f8, replyNumber=0, likeNumber=63, createdTime=2019-05-08, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6146163896f8, moduleTitle=原发性子宫及双侧附件弥漫性大B细胞淋巴瘤1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6146163896f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1702555, encodeId=1b871e0255580, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, objectTitle=鞍区粘膜相关性B细胞淋巴瘤1例, objectType=article, longId=161101, objectId=3eef16110132, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eef16110132, replyNumber=0, likeNumber=70, createdTime=2019-10-04, rootId=0, userName=marlenexl, userId=201630414353, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eef16110132, moduleTitle=鞍区粘膜相关性B细胞淋巴瘤1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eef16110132)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

细胞淋巴瘤

2020-05-29

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

MD安德森癌症中心开发的新药物，可有效克服套细胞淋巴瘤对依鲁替尼的耐药性

2019-05-17

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

来那度胺在弥漫性大B细胞淋巴瘤中的应用继续闪耀

2019-09-07

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：抗生素抑制皮肤T细胞淋巴瘤患者肿瘤和疾病活动

2019-09-12

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

膀胱弥漫大B细胞淋巴瘤侵及回肠1例

2019-12-18

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则

2019-12-19

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：Venetoclax联合R-CHOP可安全有效治疗弥漫性大B细胞淋巴瘤

2019-05-10

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Clin Cancer Res:弥漫性大B细胞淋巴瘤（DLBCL）治疗耐药新机制

2019-10-22

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

【2018 CSH】吴德沛教授：CAR-T 中国应用与发展——在B细胞淋巴瘤治疗领域大放异彩

2019-05-17

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：皮肤T细胞淋巴瘤：循环肿瘤细胞的皮肤定植

2019-09-26

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NCCN临床实践指南：B细胞淋巴瘤（2019.V3）

2020-04-27

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

B细胞淋巴瘤治疗：即使CAR-T疗法失败，还有双特异性抗体REGN1979

2019-06-19

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

NEJM：Tisagenlecleucel治疗复发或难治性弥漫性大B细胞淋巴瘤II期结果显著

2019-03-05

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

加拿大批准Yescarta（Axicabtagene Ciloleucel）CAR T疗法治疗成人复发或难治性大B细胞淋巴瘤

2019-03-09

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet oncol：VR-CAP疗法相比R-CHOP可显著延长套细胞淋巴瘤患者的总体存活期

2019-04-27

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Lancet oncol：Polatuzumab vedotin联合免疫化疗用于弥漫性大B细胞淋巴瘤的安全性和疗效

2019-10-03

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：PD-L1在ALK+间变性大细胞淋巴瘤中表达上调的分子机制

2020-03-27

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：弥漫性大B细胞淋巴瘤CD37基因免疫优势位点的高发突变

2020-05-04

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

Blood：I期临床试验：依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤

2019-05-02

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

原发性子宫及双侧附件弥漫性大B细胞淋巴瘤1例

2019-05-08

marlenexl (审核中...)

前往app查看评论内容

#细胞淋巴瘤#

鞍区粘膜相关性B细胞淋巴瘤1例

2019-10-04

科室
- - 订阅+
  - 更多科室
工具
服务